Navigation Links
MiMedx Announces Record Second Quarter Results
Date:7/31/2013

ginal treatment group.

The Company's scientific study "Biological Properties of Dehydrated Human Amnion/Chorion Grafts: Implications for Chronic Wound Healing" has been accepted for publication in the International Wound Journal, with an electronic publication date expected early next month. In the near future, we will be submitting additional papers that further describe the effects of our PURION® processed tissue.  These studies involve determining the source of the stem cells, establishing the angiogenic properties of dehydrated human amnion/chorion membrane (dHACM), and gaining an in depth understanding of various mechanisms of action in wound healing," concluded Petit.

During the quarter, MiMedx was granted three new patents for the Company's proprietary AmnioFix® and EpiFix® technologies. "These three newly issued patents now give us a total of eight dHACM-based U.S. patents that have been issued to MiMedx®," commented Taylor.  "Allografts from our proprietary AmnioFix® and EpiFix® technologies are continuing to gain excellent reception among the physician community and the private and public sector insurance carriers. Accordingly, we continue to be extremely diligent about the protection of our AmnioFix® and EpiFix® intellectual property. Currently, our patent counsel is reviewing certain issues related to potential infringement of our intellectual property rights by competing products. We are committed to ensuring that our intellectual property rights are respected."

MiMedx began its three step physical relocation to the Company's new 80,000 square feet facility during June. "Our corporate headquarters functions have completed their respective moves. Our processing and operations will be moving in the second phase. We expect the first half of processing to move in August and the balance of processing to be completed in October. With such a major undertaking, we have conting
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
2. MiMedx To Exceed High End Of Second Quarter Guidance
3. MiMedx to Ring NASDAQ Stock Market Opening Bell
4. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
5. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
6. MiMedx Announces Record First Quarter 2013 Results
7. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
8. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
9. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
10. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
11. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Asia-Pacific bromine market, and ... , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... will be Centerpiece to Expansion of ... Radiation Oncology Facility, ... ), a global leader in the field of radiosurgery,today announced ... Robotic Radiosurgery System to further expand treatment,offerings for its nationally ...
... 24 United,Therapeutics Corporation (Nasdaq: UTHR ) ... quarter financial results before the open of market,on ... host a half-hour teleconference on Thursday,July 31, 2008, ... accessible,by dialing 1-800-603-1777, with international callers dialing,1-706-679-8129. A ...
... VEDBAEK, Denmark, July 24 Frost & Sullivan,has announced ... 2008 Growth,Strategy Leadership Award in the molecular diagnostic market. ... the molecular diagnostic,market., Exiqon was selected for this ... leader in the field of in vitro therapy selection,testing ...
Cached Biology Technology:St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 2St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 3St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 4Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 2Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 3
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... A variety of end products including jet fuel, gasoline, ... existing refineries and combinations of coal and refinery by-products, ... idea is based on the coal-to-jet fuel work that ... Caroline E. Burgess Clifford, research associate at Penn State,s ...
... tiny, spherical nanogels that uniformly release encapsulated carbohydrate-based ... transfer radical polymerization (ATRP), which will ultimately enable ... the target and to dispense the drug in ... 200 nanometers in diameter possess many unique ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... The sensor components resemble a pregnancy test ...
Cached Biology News:Coal-based fuels and products hit the refinery 2Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs 2Truly sick or simply scared? 2
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Request Info...
interferon-related developmental regulator 2...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Biology Products: